Aging : How Aging Works, How We Reverse Aging, and Prospects for Curing Aging Diseases

Michael Fossel

ISBN 10: 0443155003 / ISBN 13: 9780443155000

Editore: Elsevier Science Publishing Co Inc Mär 2024, 2024

Riguardo questo articolo

Neuware - Aging: How Aging Works, How We Reverse Aging, and Prospects for Curing Aging Diseases explains the process of aging beyond mere entropy, exposing it as a complicated and dynamic process that undercuts maintenance and permits age-related disease. With a deeper understanding of the aging process, intervention becomes both easy to understand and clinically feasible. With a solid academic approach, this proposed book builds upon the substantial work published over the past 20 years, citing the newest data, up-to-date models based upon that data, and the implications for improved clinical intervention, including recent developments in gene and cell therapy. Coverage of age-related diseases includes neurodegenerative, cardiovascular, bone and joint, immune system, renal, pulmonary, and skin aging. Future directions of the field focus on interventions, including a summary of previous attempts to intervene in aging and age-related disease, the status of current research, and proposed biotech interventions, as well as their potential obstacles, risks, and benefits. This is the perfect reference for scientists, clinicians, and researchers interested in the translational research opportunities such as drug discovery, pharmacogenetics, and experimental therapeutics, not only summarizing where the field stands, but giving a clear and cogent view of where clinical medicine is going in the next decade. Codice articolo 9780443155000

Dati bibliografici

Titolo: Aging : How Aging Works, How We Reverse ...

Casa editrice: Elsevier Science Publishing Co Inc Mär 2024

Data di pubblicazione: 2024

Legatura: Taschenbuch

Condizione: Neu

Descrizione articolo

Riassunto:

Aging: How Aging Works, How We Reverse Aging, and Prospects for Curing Aging Diseases explains the process of aging beyond mere entropy, exposing it as a complicated and dynamic process that undercuts maintenance and permits age-related disease. With a deeper understanding of the aging process, intervention becomes both easy to understand and clinically feasible. With a solid academic approach, this proposed book builds upon the substantial work published over the past 20 years, citing the newest data, up-to-date models based upon that data, and the implications for improved clinical intervention, including recent developments in gene and cell therapy. Coverage of age-related diseases includes neurodegenerative, cardiovascular, bone and joint, immune system, renal, pulmonary, and skin aging. Future directions of the field focus on interventions, including a summary of previous attempts to intervene in aging and age-related disease, the status of current research, and proposed biotech interventions, as well as their potential obstacles, risks, and benefits. This is the perfect reference for scientists, clinicians, and researchers interested in the translational research opportunities such as drug discovery, pharmacogenetics, and experimental therapeutics, not only summarizing where the field stands, but giving a clear and cogent view of where clinical medicine is going in the next decade.

Informazioni sull?autore:

Dr. Fossel has an MD and a PhD in neurobiology from Stanford University where he taught neurobiology and research methods. A clinical professor of medicine, he is considered to be the world foremost expert on telomeres, aging, and age-related disease. He gave the first talk at the NIH on reversal of human aging, published the first articles on the potential of telomeres as a clinical intervention, and authored the first and only medical textbook in this field. He was editor-in-chief of Rejuvenation Research and the director of the American Aging Association, and as well as the current Editor-in-Chief OBM Geriatrics. He has authored more than 100 books, chapters, and articles, including The Telomerase Revolution, which the Wall Street Journal praised as one of the best science books of the year. He is the president of Telocyte, a biotech firm taking telomere therapy to FDA human trials. He has fulfilled numerous invitations to chair academic conferences and give opening keynotes.